Nevertheless, in a mediation analysis of the effects of liraglutide 1.8 mg in the LEADER trial [32], the CVD risk reduction was associated mainly with HbA 1c reductions, whereas contributions from other measured parameters (except a weak contribution from improvements in the urine albumin-to-creatinine ratio) were small
Serious but rarer risks include pancreatitis, gallbladder disease, and increased heart rate
Watch for nausea, lightheadedness, or blood sugar changes in the meantime
However, significant weight loss from GLP-1 therapy may modestly improve baseline testosterone levels in men with obesity-related hypogonadism, potentially allowing some patients to optimize TRT dosing downward
Researchers believe estrogen may strengthen the way GLP 1 signals the brain, leading to better appetite control and improved metabolic function
When should I not take semaglutide